TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Efficacy of Hair Sparing Radiotherapy Treatment to the Whole Brain.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults over 18~* Positive cancer diagnosis~* Either proven brain metastasis or prophylaxis for primary lung cancer~* Have no epilating chemotherapy planned~* Basic understanding of English~Exclusion Criteria:~* Previous whole brain radiotherapy~* Pregnant females~* Unable to give informed consent~* Urgent cases that need same or next day treatment when referred

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VMAT WBRT (Type: None): Patients requiring whole brain radiotherapy as part of their cancer managment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Use of ARA290 for the Treatment of Diabetic Macular Oedema

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with DR and centre involving DMO with a central subfield thickness of \> 400 microns, as determined using SD-OCT;~2. \>= 18 years of age~3. Clear media and naïve to previous treatments for DMO.~Exclusion Criteria:~1. Macular oedema related to other retinal disease~2. Hazy media that prevents adequate retinal imaging~3. Allergy to fluorescein~4. Previous treatments for DMO~5. DMO with central subfield thickness of \< 400 microns~6. Patients on systemic or topical steroids~7. Use of erythropoiesis stimulating agents within the two months prior to screening or during the trial~8. Treated with any other investigational medication or device within 60 days~9. Pregnant women, women who have not yet reached the menopause (no menses for 12 months or more without an alternative medical cause) who test positive for pregnancy or who are unwilling to take a pregnancy test prior to trial entry or are unwilling to undertake adequate precautions to prevent pregnancy for the duration of the trial.~10. Men who have a female partner and who are unwilling to undertake adequate precautions to prevent pregnancy for the duration of the trial.~11. Female patients who are breastfeeding~12. Active proliferative diabetic retinopathy (PDR) requiring treatment.~13. Patients with other eye diseases besides DR~14. Patients who are unable or unwilling to commit to the study schedule of events~15. Serious illness that is likely to affect the patient's ability to complete the study~Any patient showing a clinically significant improvement between the initial screening and presenting for the first screening/baseline visit may no longer be eligible for the study and will be recorded as a screen failure and will not be entered on to the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: OTHER): Subcutaneous daily injection of ARA 290 at a dose of 4mg for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Anterior Defect Correction With Mesh Plus Treatment of Stress Incontinence With Transobturator or Transvaginal Approach

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cystocele~* Genuine stress urinary incontinence by self report, examination and test~* Urethral hypermobility~* Eligible for both surgical procedures~* Ambulatory~Exclusion Criteria:~* Pregnancy~* \<12 months post-partum~* Systemic disease and/or drugs known to affect bladder function~* Current chemotherapy or radiation therapy~* Urethral diverticulum, augmentation cytoplasty, or artificial sphincter~* Recent pelvic surgery~* Previous pelvic or anti-incontinence surgery~* History of severe abdominopelvic infections~* Known extensive abdominopelvic adhesions~* Detrusor instability and/or intrinsic sphincter dysfunction~* Other gynaecologic pathologies (eg, fibroids, ovarian cysts)~* BMI \>30

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Transobturatory correction of anterior defect plus TOT
- 2 (Type: ACTIVE_COMPARATOR): Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of malignant melanoma~* Metastatic Stage IV disease, or Stage III disease that is not surgically resectable~* ECOG Performance status of 0,1,or 2~* Adequate venous access~* Agreement to practice effective methods of birth control~* Hepatically impaired consistent with Child-Pugh classification Grade B~Exclusion Criteria:~* Chronic intravascular coagulopathy confirmed by the presence of fibrinogen degradation products, metastases to the liver, or exudative ascites~* Prior organ allograft~* Requirement for concomitant anticoagulant therapy (with the exception of 1 mg/day of warfarin for central line prophylaxis) while receiving protocol therapy~* Known hypersensitive to DTIC~* Prior treatment with Genasense

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* histologically confirmed mycosis fungoides stage I-II with failure to obtain full remission after standard PUVA treatment or relapse within 4 months of PUVA treatment~Exclusion Criteria:~* under 18 years, pregnancy, other somatic diseases with a life expentancy under 1/2 years, psycological disorder preventing the patient to understand the information and cooperate in the treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Proven to carry a pathogenic germline mutation in a DNA mismatch repair gene causing Lynch syndrome (hereditary non-polyposis colorectal cancer) (usually MSH2, MLH1, or MSH6)~* Meets both of the following criteria:~  * Has a family history of Lynch syndrome according to the following Amsterdam or modified Amsterdam criteria:~    * Three relatives with a Lynch syndrome-related cancer (colorectal, small bowel, endometrial, ovarian, urothelial, or hepatobiliary)~   * One is a first-degree relative of the other two~   * Two generations affected~   * One relative diagnosed before age of 50~ * Personal history of colorectal cancer (i.e., a large, villous, or severely dysplastic colorectal adenoma) before the age of 40 OR history of small bowel, hepatobiliary, or urothelial cancer AND has an affected family member with an abnormal tumor immunohistochemistry staining for Lynch syndrome~* No active genital malignancy, breast carcinoma, or other estrogen dependent tumor~  * History of genital malignancy, breast carcinoma, or other estrogen dependent tumor allowed at the discretion of the investigator~PATIENT CHARACTERISTICS:~* Must have an intact uterus and not planning to undergo a prophylactic hysterectomy~* Not pregnant~* Not planning to become pregnant within the next 3 years~* No abortion resulting in infection within the past 3 months~* No pelvic inflammatory disease (PID) within the past 6 months or recurrent PID~* No clinically significant submucous myomas requiring treatment~  * Small subserous or intramural myomas, clinically assessed as insignificant allowed~* No known hypersensitivity to the constituents of the Mirena® IUS~* No unresolved abnormal cervical smear and/or current cervical dysplasia~* No trophoblastic disease with elevated hCG levels~* No liver tumor or other acute or severe liver disease~* No clinically significant condition or laboratory result that might, in the opinion of the investigator, compromise patient safety, interfere with evaluations, or prevent completion of the study~* No other active malignancy~* No history of stroke or myocardial infarction~* No history of bacterial endocarditis or severe pelvic infection after any prosthetic valve replacement or in patients with an anatomical lesion of the heart~PRIOR CONCURRENT THERAPY:~* No other concurrent use of intrauterine devices~* No concurrent therapy for cancer

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MEV for Retroclavicular Approach to Infraclavicular Block

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients who received infraclavicular brachial plexus block for elective elbow, forearm, wrist, or hand surgery~* American Society of Anesthesiologists class I, II or III~Exclusion Criteria:~* patients \<18 years old~* \>65 years old~* body mass index (BMI) \<20 or \>35 kg/m2~* inability to provide written informed consent~* refusal of regional anesthesia~* pregnancy~* contraindication for regional anesthesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Perianal Crohn's Disease, Combining Medical and Surgical Treatment.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Perianal fistula of Crohn's dis~Exclusion Criteria:~* More then 2 fistulae perianal sepsis known contraindication to infliximab or glue

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of South African Dialysis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients undergoing chronic haemodialysis or peritoneal dialysis~* Commenced Aranesp therapy 3-6 months prior to enrolment~* Erythropoiesis stimulating agent (ESA) naive or treated with another ESA prior to commencing Aranesp~* Informed consent obtained~Exclusion Criteria:~* Received Aranesp in an interventional study within 6 months prior to start of observation period~* Receive investigational product during the observation period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Study population (Type: None): Single cohort of dialysis patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Use of ProKera Plus® in the Management of Bacterial Corneal Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion Criteria~  * Subjects 18 years of age or older, all sexes and races~ * Willing to sign a written informed consent to participate~ * Corneal ulcer criteria: at least 3mm in diameter, opacification located within 3mm of visual axis, infiltrate occupying at least 50% of the corneal thickness, moderate AC cell reaction, clinical picture consistent with bacterial infection later confirmed by culture and gram stain.~Exclusion Criteria:~* History of Immunodeficiency~* History of connective tissue disorders or severe atopic disease~* History of chemical eye injuries~* History of known limbal stem cell deficiency~* History of neurotrophic keratopathy~* History of recent eye surgery, or glaucoma surgery with bleb or drainage tube~* Risk factors and clinical appearance consistent with fungal keratitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional Treatment (Type: NO_INTERVENTION): * Corneal ulcer scraping sent for microbial culture~* Admission to the hospital for initiation of fortified vancomycin 25mg/mL every 1 hour alternating with fortified tobramycin 15mg/mL every 1 hour, preservative free artificial tears every 2 hours, and doxycycline 100mg twice daily.~After 48 hours of conventional treatment, consent will be obtained regarding the use of experimental treatment with ProKera Plus® versus continuing conventional method of treatment
- ProKera Plus® Treatment (Type: EXPERIMENTAL): 1. Experimental Treatment Arm , ProKera Plus® will be placed in the eye with the corneal ulcer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Noninvasive Glucose Measurements - Database and Calibration Compilation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with and without diabetes including pregnant women~Exclusion Criteria:~* Subject under 18 years of age~* Subjects not able to understand provided information~* Subjects without measuring sites~* Subjects with rash or wound on measuring sites~* Subjects with stained fingers, such a oil or nicotine~* Subjects not capable of holding arm/hand steadily on probe~* Subjects with thrombosis in arm/hand

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- OUH protocol (Type: EXPERIMENTAL): The protocol constituted two outpatient visits in the clinic within one week. Each visit had a duration of approximately 2,5 hours. Prior to study, optical screenings were conducted:~* Optical Coherence Tomography (OCT)~* Optical screening on measuring site with WM3.4.~Subjects were measured by the following scheme: ABL measurement, two optical measurements on WM3.4 #1 followed by two optical measurements on WM3.4 #2.
- Home 1 protocol (Type: EXPERIMENTAL): Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital.~WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue was used for reference.
- Home 2 protocol (Type: EXPERIMENTAL): Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital.~WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue and CGM/FGM was used for reference.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Three Tissue Acquiring Techniques During EUS Guided Biopsies of Solid Tumors.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Ages between 18-80 years old~2. Sex: male or female~3. Patients who require EUS and tissue sampling of solid solid lesions (size \>1 cm) anywhere in the following locations: lymph nodes, stomach, esophagus, colon, small intestine, pancreas, liver, spleen or kidney.~4. Patients who are able to give consent~Exclusion Criteria:~1. Pregnant female~2. Coagulation disorders (platelets \< 50,000/mm3, INR \> 2)~3. Patients with acute pancreatitis in the immediate 2 weeks prior to the procedure.~4. Cardiorespiratory dysfunction that precludes sedation.~5. Unable to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Wet suction (Type: EXPERIMENTAL): This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the wet suction technique
- Dry suction (Type: EXPERIMENTAL): This arm will include all the patients that will get and endoscopic ultrasound guided fine needle biopsy done with the dry suction technique
- Slow pull (Type: EXPERIMENTAL): This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the slow pull technique

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of recurrent kidney stone disease based on ≥2 stone events with a minimum of 1 stone event within 5 years prior to screening~* Meets the 24 hour urine oxalate excretion requirements~* The 2 most recently analyzed kidney stones prior to randomization contained 50% or more of calcium oxalate; if only one stone analysis is available, then it must have contained 50% or more of calcium oxalate~Exclusion Criteria:~* Known history of secondary causes of elevated urinary oxalate and/or recurrent kidney stones~* Primary hyperoxaluria~* Estimated glomerular filtration rate (eGFR) of \<30 mL/min/1.73m\^2 at screening~* Received an investigational agent within the last 30 days or 5 half-lives, whichever is longer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lumasiran Dose 1 (Type: EXPERIMENTAL): Participants will be administered lumasiran by subcutaneous (SC) injection.
- Lumasiran Dose 2 (Type: EXPERIMENTAL): Participants will be administered lumasiran by SC injection.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will be administered placebo by SC injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Expanding Access to Home-Based Palliative Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older;~2. diagnosis of HF, COPD, or advanced cancer;~3. one or more hospitalizations or ED visits in the previous year;~4. an Australia-Modified Karnofsky Performance Scale score of 70% or less; and~5. English- or Spanish-speaking.~Exclusion Criteria:~1. is receiving hospice care;~2. has end-stage renal disease; and/or~3. lives in a nursing home.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Home-based Palliative Care (Type: EXPERIMENTAL): Home-based palliative care features home visits by an interdisciplinary PC team (physician, nurse, social worker, and chaplain) that provides pain and symptom management, psychosocial support, advance care planning, disease management education, spiritual and grief counseling, and other services as needed.
- Enhanced Usual Care (Type: ACTIVE_COMPARATOR): Enhanced usual care refers to: 1) usual primary care provided by a primary care physician who has been offered special training in the core elements of palliative care; 2) case management services; and 3) provider support through palliative care consultation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues